Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

Pemetrexed 9Nivolumab 8Cisplatin 8Carboplatin 8pembrolizumab 7130-nm albumin-bound paclitaxel 7Gemcitabine 6padeliporfin 5durvalumab 5Paclitaxel 5Bevacizumab 5palbociclib 4napabucasin 4atezolizumab 4Irinotecan 4Fulvestrant 4Fluorouracil 4Drug Therapy 4Cyclophosphamide 4ribociclib 3osimertinib 3cobimetinib 3alectinib 3abemaciclib 3Trastuzumab 3Sunitinib 3Radiosurgery 3Mitomycin 3Docetaxel 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡